Evidence map›Paper›PMID 25240614›Full record

ArticleBioorganic & medicinal chemistry letters2014

The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.

Quaovi Sodji, Vishal Patil, Surendra Jain, James R Kornacki, Milan Mrksich, Babu L Tekwani, Adegboyega K Oyelere

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Quaovi SodjiSchool of Chemistry and Biochemistry, Parker H. Petit for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
Vishal PatilSchool of Chemistry and Biochemistry, Parker H. Petit for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA.
Surendra JainNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA.
James R KornackiDepartment of Chemistry and Biomedical Engineering, Northwestern University, 2145 Sheridan Rd, Evanston, IL 60208-3113, USA.
Milan MrksichDepartment of Chemistry and Biomedical Engineering, Northwestern University, 2145 Sheridan Rd, Evanston, IL 60208-3113, USA.
Babu L TekwaniNational Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA. Electronic address: btekwani@olemiss.edu.
Adegboyega K OyelereSchool of Chemistry and Biochemistry, Parker H. Petit for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332-0400, USA. Electronic address: aoyelere@gatech.edu.

Funding

Nonpeptide macrocyclic histone deacetylase (HDAC) inhibitors for targeted lung caR01CA131217 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI OYELERE, ADEGBOYEGA · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA131217NCI NIH HHS R01CA131217
6 · The paper itself

Abstract

Histone deacetylase inhibitors (HDACi) pleiotropy is largely due to their nonselective inhibition of various cellular HDAC isoforms. Connecting inhibition of a specific isoform to biological responses and/or phenotypes is essential toward deconvoluting HDACi pleiotropy. The contribution of classes I and II HDACs to the antileishmanial activity of HDACi was investigated using the amastigote and promastigote forms of Leishmania donovani. We observed that the antileishmanial activities of HDACi are largely due to the inhibition of HDAC6-like activity. This observation could facilitate the development of HDACi as antileishmanial agents.

Indexed as

Antiprotozoal AgentsDose-Response Relationship, DrugHistone Deacetylase InhibitorsHistone DeacetylasesIsoenzymesLeishmania donovaniMolecular StructureParasitic Sensitivity TestsStructure-Activity RelationshipAntiprotozoal AgentsHistone Deacetylase InhibitorsHistone DeacetylasesIsoenzymes3-Hydroxypyridin-2-thioneHistone deacetylase inhibitorsLeishmania donovaniTrichostatin ATubastatin A

Identifiers

PMID25240614
PMCPMC4225773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.